Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Boston Scientific ( (BSX) ) has provided an update.
Boston Scientific said its board on Feb. 18, 2026, expanded from 10 to 12 members and elected Starbucks chief financial officer Cathy Smith and Takeda Pharmaceutical chief executive Christophe Weber as directors, with committee assignments effective Feb. 23, 2026. The appointments, which follow the planned 2026 retirements of directors John Sununu and Yoshiaki Fujimori, add deep finance and global pharma leadership to the board as the company pursues innovation, disciplined growth and enhanced patient care.
On the same day, the board also approved a $4 billion increase to the company’s stock repurchase authorization, raising the total program capacity to $5 billion, all of which remained available at the time of the decision. The enlarged buyback program signals continued confidence in Boston Scientific’s financial position and may bolster shareholder returns, while the new board appointments strengthen governance and strategic oversight during a period of ongoing global expansion in medical technologies.
The most recent analyst rating on (BSX) stock is a Buy with a $110.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.
Spark’s Take on BSX Stock
According to Spark, TipRanks’ AI Analyst, BSX is a Outperform.
The score is driven primarily by strong underlying financial performance and a bullish earnings-call outlook with solid growth, margin expansion, and free-cash-flow guidance. These positives are tempered by very weak technicals (sharp downtrend/negative momentum) and a premium valuation (high P/E), with incremental execution/regulatory risk from the Penumbra deal.
To see Spark’s full report on BSX stock, click here.
More about Boston Scientific
Boston Scientific is a global medical technology company that develops and manufactures devices and therapies used to diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological conditions. With more than 45 years in the industry, the company focuses on advancing science through high-performance solutions that address unmet patient needs and help reduce healthcare costs worldwide.
Based in Marlborough, Mass., Boston Scientific serves physicians and health systems around the world and positions itself as a leader in innovative medical technologies. Its broad portfolio supports procedures across multiple specialties, reinforcing its role in improving patient outcomes while maintaining a strategic emphasis on disciplined growth and operational efficiency.
Average Trading Volume: 13,554,867
Technical Sentiment Signal: Hold
Current Market Cap: $113.2B
For detailed information about BSX stock, go to TipRanks’ Stock Analysis page.